STOCK TITAN
  1. Home
  2. News
  3. TCBP

TC BioPharm (Holdings) plc - TCBP STOCK NEWS

Welcome to our dedicated news page for TC BioPharm (Holdings) plc (Ticker: TCBP), a resource for investors and traders seeking the latest updates and insights on TC BioPharm (Holdings) plc.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect TC BioPharm (Holdings) plc's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of TC BioPharm (Holdings) plc's position in the market.

News
TC BioPharm Announces Streamlined Efficiencies and Reduces Overhead with Selection of Single Global CRO for Clinical Trials
Rhea-AI Summary
TC BioPharm has selected Fortrea as its Contract Research Organization (CRO) for global trials, including ACHIEVE and ACHIEVE2. The trials will be managed by Fortrea, creating a vertically integrated clinical trial program that aims to increase operational efficiencies and improve data management. TC BioPharm expects to generate cash savings by consolidating CRO services under a single entity.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.53%
Tags
clinical trial
-
News
TC BioPharm Selects Excellos as CDMO in Anticipation of Expanded US Clinical Trial Requirements
Rhea-AI Summary
TC BioPharm selects Excellos as a partner for its US clinical trial efforts. Excellos will provide allogeneic cell banks to bridge donor blood with the final product. The partnership aims to enhance clinical trial success and optimize the final product.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.17%
Tags
clinical trial
-
News
TC BioPharm Announces Submission of Investigational New Drug (IND) Application to U.S. FDA for Treatment of Relapse/Refractory AML
Rhea-AI Summary
TC BioPharm submits an Investigational New Drug (IND) application for TCB-008 in the treatment of relapse/refractory Acute Myeloid Leukemia.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10%
Tags
none
News
TC BioPharm to Present at the LD Micro Main Event XVI
Rhea-AI Summary
TC BioPharm to present at LD Micro Main Event conference on October 3-5, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.05%
Tags
conferences
-
News
TC BioPharm Announces Grant Funding in Collaboration with Queen Mary University of London (QMUL)
Rhea-AI Summary
TC BioPharm has entered into a collaboration agreement with Queen Mary University of London to research the therapeutic potential of gamma-delta T cells for the treatment of mucosal infections. The collaboration received grant funding from The Impact Fund arm of QMUL. TC BioPharm will be working with Dr. Neil McCarthy's lab at QMUL. The project is financed by The Queen Mary Impact Fund and aims to understand how gamma-delta T-cell function can be restored by novel immunotherapies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.75%
Tags
none
-
News
TC BioPharm Maintains Nasdaq Listing
Rhea-AI Summary
TC BioPharm regains compliance with Nasdaq Stock Market Listing Rule 5550(b)(2), maintaining listing on Nasdaq Global Select Market. The company had previously received a letter indicating non-compliance with the minimum Market Value of Listed Securities requirement. TC BioPharm submitted a plan to regain compliance and has now been notified of regaining compliance with shareholder equity concerns. The company will be subject to a Mandatory Panel Monitor for one year.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.73%
Tags
none
News
TC BioPharm CEO, Bryan Kobel, is Featured on The Stock Day Podcast
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.35%
Tags
none
-
News
TC BioPharm to Present at LD Micro Invitational XIII Conference on June 7, 2023
Rhea-AI Summary
TC BioPharm (Holdings) PLC, a clinical stage biotechnology company, will be presenting at the LD Micro Invitational XIII Conference in Los Angeles, CA from June 6 - 8, 2023. The presentation will be held on June 7, 2023 at 2:00 pm ET. TC BioPharm CEO, Bryan Kobel, will be speaking at the conference. For more information or to schedule a meeting, please contact ir@tcbiopharm.com.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.14%
Tags
conferences
-
News
TC BioPharm Increases Allogeneic Car and Partnering Focus for Advancement of TCB-008
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.14%
Tags
none
News
TC BioPharm to Present at the Sequire Investor Summit in Puerto Rico
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.32%
Tags
conferences
Stock TCBP logo
TC BioPharm (Holdings) plc

Nasdaq:TCBP

TCBP Rankings

N/A Ranked by Market Cap
N/A Ranked by Stock Gains
N/A Ranked by Dividends

TCBP Stock Data

5.14M
63.77M
0.03%
2.41%
8.43%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
United Kingdom
Motherwell